LGND
NASDAQ · Pharmaceuticals
Ligand Pharmaceuticals
$204.56
+2.90 (+1.44%)
Financial Highlights (FY 2026)
Revenue
177.23M
Net Income
-4,274,642
Gross Margin
93.4%
Profit Margin
-2.4%
Rev Growth
-15.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.4% | 93.4% | 55.6% | 55.6% |
| Operating Margin | -13.5% | -12.2% | 24.0% | 26.4% |
| Profit Margin | -2.4% | -2.3% | 27.4% | 27.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 177.23M | 209.76M | 944.72M | 909.17M |
| Gross Profit | 165.48M | 195.86M | 525.52M | 505.75M |
| Operating Income | -23,979,071 | -25,542,861 | 226.35M | 240.08M |
| Net Income | -4,274,642 | -4,553,412 | 258.92M | 249.74M |
| Gross Margin | 93.4% | 93.4% | 55.6% | 55.6% |
| Operating Margin | -13.5% | -12.2% | 24.0% | 26.4% |
| Profit Margin | -2.4% | -2.3% | 27.4% | 27.5% |
| Rev Growth | -15.5% | -15.5% | +8.5% | +8.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 257.30M | 195.72M |
| Total Equity | — | — | 1.39B | 1.23B |
| D/E Ratio | — | — | 0.19 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -31,291,776 | -35,184,267 | 346.84M | 320.13M |
| Free Cash Flow | — | — | 167.31M | 167.23M |